Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
Alexandrescu
Doru T
DT
Popoveniuc
Geanina
G
Farzanmehr
Haleh
H
Dasanu
Constantin A
CA
Dawson
Nancy
N
Wartofsky
Leonard
L
D000888:Antibodies, Anti-Idiotypic / Q000097:blood*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D044963:Biopsy, Fine-Needle; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D013961:Thyroid Gland / Q000276:immunology* / Q000473:pathology; D013967:Thyroiditis, Autoimmune / Q000097:blood / Q000139:chemically induced* / Q000276:immunology*; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D000888:Antibodies, Anti-Idiotypic; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D014284:Triiodothyronine; D013972:Thyrotropin; D013974:Thyroxine; D000077210:Sunitinib